CD22 and diffuse large B-cell lymphoma: In this study, we engineered CD19/CD22 BS Loop CAR-T cells with an enhanced targeting efficacy for CD22 and assessed their safety and effectiveness in patients with relapsed/refractory diffuse large B-cell lymphoma.